期刊文献+
共找到1,609篇文章
< 1 2 81 >
每页显示 20 50 100
Atypical Guillain-Barrésyndrome with positive anti-sulfatide,anti-GT1b,and anti-GT1a antibodies:A case report
1
作者 Fei-Fei Tan He-Xu Liu +2 位作者 Xue-Yan Huang Chang-Yin Yu Xiao-Yan Yang 《World Journal of Clinical Cases》 SCIE 2024年第20期4372-4376,共5页
BACKGROUND The role of diverse antibodies in mediating peripheral nerve injury in Guillain-Barrésyndrome(GBS)is becoming clearer,but positivity for multiple antibodies in one case is uncommon.To our knowledge,thi... BACKGROUND The role of diverse antibodies in mediating peripheral nerve injury in Guillain-Barrésyndrome(GBS)is becoming clearer,but positivity for multiple antibodies in one case is uncommon.To our knowledge,this is the first case involving GBS with positive anti-sulfatide,anti-GT1a,and anti-GT1b antibodies.CASE SUMMARY A 20-year-old female patient was admitted to the hospital due to weakness of limbs for 5 d,and deterioration of the weakness and muscle aches for 1 d.The patient's limbs were weak,but the tendon reflexes in the part of the limbs were normal.There was no comorbid peripheral nociception or deep sensory dysfunction.She was diagnosed with GBS and was discharged after receiving intravenous human immunoglobulin pulse therapy.CONCLUSION In this article,the clinical manifestations,neurophysiological examination,and auxiliary examination findings of a GBS patient positive for multiple antibodies were analyzed to improve the identification of the disease by clinical physicians at an early stage. 展开更多
关键词 Guillain-barré Anti-sulfatide antibody Anti-GT1b antibody Anti-GT1a antibody Case report
下载PDF
Anti-OX40 Antibody Combined with HBc VLPs Delays Tumor Growth in a Mouse Colon Cancer Model
2
作者 LIU Jia Jia SU Qiu Dong +2 位作者 YI Yao SHEN Li Ping BI Sheng Li 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2024年第2期187-195,共9页
Objective Combination immunotherapy strategies targeting OX40,a co-stimulatory molecule that can enhance antitumor immunity by modulating the proliferation,differentiation,and effector function of tumor-infiltrating T... Objective Combination immunotherapy strategies targeting OX40,a co-stimulatory molecule that can enhance antitumor immunity by modulating the proliferation,differentiation,and effector function of tumor-infiltrating T cells,have attracted much attention for their excellent therapeutic effects.In this study,we aimed to evaluate the antitumor efficacy of combined anti-OX40 and hepatitis B core viruslike particles(HBc VLPs)therapy using a mouse colon cancer model.Methods Humanized B-h OX40 mice were injected subcutaneously with MC38 colon tumor cells and treated with HBc VLPs+anti-h OX40 antibody.Tumor growth was monitored.Flow cytometric analysis was performed to evaluate the populations of T cell subsets in the tumors.Results The combination of anti-OX40 with HBc VLPs resulted in a significant delay in tumor growth,suggesting that a potent antitumor immunity was induced by the combination therapy.Further studies revealed that HBc VLPs+anti-OX40 treatment induced a significant increase in effector T cells(Teffs)and a significant decrease in regulatory T cells(Tregs)in the tumor microenvironment(TME),which accounted for the synergistic antitumor effect of anti-OX40 in combination with HBc VLPs.Conclusion Combination therapy of anti-h OX40 and HBc VLPs provides synergistic antitumor activity in colon cancer-bearing mice,which may represent a potential design strategy for cancer immunotherapy. 展开更多
关键词 Anti-OX40 antibody Hepatitis b core virus-like particles Tumor Combination therapy
下载PDF
Miller fisher syndrome with positive anti-GQ1b/GT1a antibodies associated with COVID-19 infection:A case report
3
作者 Cheng-Qun Wei Xuan Yu +1 位作者 Yuan-Yuan Wu Qing-Jie Zhao 《World Journal of Clinical Cases》 SCIE 2024年第31期6500-6505,共6页
BACKGROUND Miller fisher syndrome(MFS)is a variant of Guillain-Barrésyndrome,an acute immune-mediated peripheral neuropathy that is often secondary to viral infections.Anti-ganglioside antibodies play crucial rol... BACKGROUND Miller fisher syndrome(MFS)is a variant of Guillain-Barrésyndrome,an acute immune-mediated peripheral neuropathy that is often secondary to viral infections.Anti-ganglioside antibodies play crucial roles in the development of MFS.The positive rate of ganglioside antibodies is exceptionally high in MFS patients,particularly for anti-GQ1b antibodies.However,the presence of other ganglioside antibodies does not exclude MFS.CASE SUMMARY We present a 56-year-old female patient who suddenly developed right blepharoptosis and progressively worsening vision in both eyes.There were flu symptoms prior to onset,and a coronavirus disease 2019 test was positive.On physical examination,the patient exhibited bilateral extraocular muscle paralysis,weakened reflexes in both limbs,and impaired coordination.The cerebrospinal fluid examination results showed no obvious abnormalities.Bilateral peroneal nerve F-waves were not extracted.Serum anti-GD1b IgG and anti-GT1a IgG antibodies were positive.The patient received intravenous methylprednisolone(1000 mg/day),with the dosage gradually decreased.Additionally,intravenous high-dose immunoglobulin treatment was administered for 5 days(0.4 g/kg/day)from day 2 to day 6 of hospitalization.The patient’s symptoms improved after treatment with immunoglobulins and hormones.CONCLUSION Positive ganglioside antibodies may be used as supporting evidence for the diagnosis;however,the diagnosis of MFS is more reliant on clinical symptoms. 展开更多
关键词 Miller fisher syndrome Guillain-barre syndrome COVID-19 Anti-GQ1b antibody Anti-GT1a antibody Case report
下载PDF
Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen:Novel viral biomarkers for chronic hepatitis B management
4
作者 Wattana Leowattana Pathomthep Leowattana Tawithep Leowattana 《World Journal of Hepatology》 2024年第4期550-565,共16页
The management of hepatitis B virus(HBV)infection now involves regular and appropriate monitoring of viral activity,disease progression,and treatment response.Traditional HBV infection biomarkers are limited in their ... The management of hepatitis B virus(HBV)infection now involves regular and appropriate monitoring of viral activity,disease progression,and treatment response.Traditional HBV infection biomarkers are limited in their ability to predict clinical outcomes or therapeutic effectiveness.Quantitation of HBV core antibodies(qAnti-HBc)is a novel non-invasive biomarker that may help with a variety of diagnostic issues.It was shown to correlate strongly with infection stages,hepatic inflammation and fibrosis,chronic infection exacerbations,and the presence of occult infection.Furthermore,qAnti-HBc levels were shown to be predictive of spontaneous or treatment-induced HBeAg and HBsAg seroclearance,relapse after medication termination,re-infection following liver transplantation,and viral reactivation in the presence of immunosuppression.qAnti-HBc,on the other hand,cannot be relied on as a single diagnostic test to address all problems,and its diagnostic and prognostic potential may be greatly increased when paired with qHBsAg.Commercial qAnti-HBc diagnostic kits are currently not widely available.Because many methodologies are only semi-quantitative,comparing data from various studies and defining universal cut-off values remains difficult.This review focuses on the clinical utility of qAnti-HBc and qHBsAg in chronic hepatitis B management. 展开更多
关键词 Quantitative hepatitis b core antibody Quantitative hepatitis b surface antigen Chronic hepatitis b management Novels viral biomarkers
下载PDF
Hepatitis B virus reactivation in patients treated with monoclonal antibodies
5
作者 Silvia De Pauli Martina Grando +1 位作者 Giovanni Miotti Marco Zeppieri 《World Journal of Virology》 2024年第1期33-37,共5页
Hepatitis B virus(HBV)reactivation poses a significant clinical challenge,espe-cially in patients undergoing immunosuppressive therapies,including mono-clonal antibody treatments.This manuscript briefly explores the c... Hepatitis B virus(HBV)reactivation poses a significant clinical challenge,espe-cially in patients undergoing immunosuppressive therapies,including mono-clonal antibody treatments.This manuscript briefly explores the complex rela-tionship between monoclonal antibody therapy and HBV reactivation,drawing upon current literature and clinical case studies.It delves into the mechanisms underlying this phenomenon,highlighting the importance of risk assessment,monitoring,and prophylactic measures for patients at risk.The manuscript aims to enhance the understanding of HBV reactivation in the context of monoclonal antibody therapy,ultimately facilitating informed clinical decision-making and improved patient care.This paper will also briefly review the definition of HBV activation,assess the risks of reactivation,especially in patients treated with monoclonal antibodies,and consider management for patients with regard to screening,prophylaxis,and treatment.A better understanding of patients at risk can help clinicians provide optimum management to ensure successful patient outcomes and prevent morbidity. 展开更多
关键词 Hepatitis b virus REACTIVATION Acute infection Chronic infection Monoclonal antibodies
下载PDF
继发于单纯疱疹病毒脑炎的抗NMDAR和抗GABA_(BR)双阳性自身免疫性脑炎1例报告及文献复习
6
作者 赵仲艳 徐志育 +3 位作者 吴婵姬 赵二义 黄丹 黄仕雄 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2024年第1期236-242,共7页
目的:分析1例单纯疱疹病毒性脑炎(HSVE)继发抗N-甲基-D-天冬氨酸受体(NMDAR)和抗γ-氨基丁酸B型受体(GABA_(BR))双阳性自身免疫性脑炎(AE)患者的临床表现及诊疗经过,以提高临床医生对该类病的认识。方法:收集1例HSVE继发抗NMDAR和抗GABA... 目的:分析1例单纯疱疹病毒性脑炎(HSVE)继发抗N-甲基-D-天冬氨酸受体(NMDAR)和抗γ-氨基丁酸B型受体(GABA_(BR))双阳性自身免疫性脑炎(AE)患者的临床表现及诊疗经过,以提高临床医生对该类病的认识。方法:收集1例HSVE继发抗NMDAR和抗GABA_(BR)双阳性AE患者的临床资料,对其诊断和治疗经过进行总结,并结合相关文献进行复习。结果:患者,男性,36岁,以头痛起病,随后出现肢体抽搐,并进展为意识障碍。入院后脑脊液常规生化检测异常,脑脊液单纯疱疹病毒1型(HSV-1) IgG抗体阳性,脑脊液和血清NMDAR抗体检测阳性,头部磁共振成像(MRI)检查提示右侧枕叶白质异常信号,诊断为HSVE继发抗NMDAR脑炎。数月后患者出现精神行为异常、认知障碍和睡眠障碍等症状,血清NMDAR抗体和GABA_(BR)抗体均阳性,诊断为HSVE继发抗NMDAR脑炎和抗GABA_(BR)脑炎。给予激素冲击和静脉注射免疫球蛋白(IVIG)治疗后,患者病情好转出院。随访1年,患者精神症状完全消失,遗留轻度认知功能障碍。结论:HSVE抗病毒治疗有效的恢复期患者临床症状再度恶化时,应高度怀疑继发AE的可能,应尽快完善自身免疫性抗体检测,以期早期诊断,早期治疗,以改善患者预后。 展开更多
关键词 单纯疱疹病毒性脑炎 抗N-甲基-D-门冬氨酸受体抗体 抗γ-氨基丁酸b型受体抗体 自身免疫性脑炎
下载PDF
乳腺癌患者病理特征与Bcl-2、CXCL13、PAX8表达情况的关系分析 被引量:1
7
作者 王洋 刘伟 +2 位作者 韩晓东 马娜 秦蕊 《检验医学与临床》 CAS 2024年第10期1431-1435,共5页
目的分析乳腺癌患者病理特征与B细胞淋巴瘤/白血病-2基因(Bcl-2)、趋化因子配体13(CXCL13)、配对盒基因8抗体(PAX8)表达情况的关系。方法收集2021年1月至2023年1月该院收治的160例乳腺癌患者临床资料。采用免疫组化法对其癌组织与癌旁组... 目的分析乳腺癌患者病理特征与B细胞淋巴瘤/白血病-2基因(Bcl-2)、趋化因子配体13(CXCL13)、配对盒基因8抗体(PAX8)表达情况的关系。方法收集2021年1月至2023年1月该院收治的160例乳腺癌患者临床资料。采用免疫组化法对其癌组织与癌旁组织Bcl-2、CXCL13、PAX8表达情况进行检测,并分析3项指标与患者病理特征的关系。结果与癌旁组织比较,癌组织Bcl-2、CXCL13、PAX8阳性率更高,差异有统计学意义(P<0.05)。与雌激素受体(ER)阴性、肿瘤最大径≥3 cm、孕激素受体(PR)阴性患者比较,ER阳性、肿瘤最大径<3 cm、PR阳性患者中Bcl-2高表达占比更高,差异有统计学意义(P<0.05);与无淋巴结转移、Ⅰ~Ⅱ期患者比较,淋巴结转移、Ⅲ~Ⅳ期患者中CXCL13高表达占比更高,差异有统计学意义(P<0.05);与Ⅰ~Ⅱ期、高/中分化、无淋巴结转移患者比较,Ⅲ~Ⅳ期、低分化、有淋巴结转移患者中PAX8高表达占比更高,差异有统计学意义(P<0.05)。ER、PR表达情况与Bcl-2表达情况呈正相关(P<0.05),肿瘤最大径与Bcl-2表达情况呈负相关(P<0.05);临床分期、淋巴结转移情况与CXCL13、PAX8表达情况呈正相关(P<0.05);分化程度与PAX8表达情况呈负相关(P<0.05)。结论乳腺癌患者Bcl-2、CXCL13、PAX8表达情况对疾病的发生和发展具有明显影响,有望成为评估乳腺癌患者病情严重程度的标志物。 展开更多
关键词 乳腺癌 b细胞淋巴瘤/白血病-2 趋化因子配体13 配对盒基因8抗体 临床病理
下载PDF
抗NMDAR脑炎中B细胞相关免疫病理机制与治疗进展
8
作者 杨素格 韩松 +5 位作者 常忠正 徐营营 周晓艳 魏艳 程玲 王允 《医学综述》 CAS 2024年第9期1025-1030,共6页
抗N-甲基-D-天冬氨酸受体(NMDAR)脑炎是自身免疫性脑炎中最常见的类型之一,其发病机制与B细胞介导的体液免疫反应产生的抗NMDAR抗体有关。抗NMDAR脑炎患者B细胞表面受体互补决定区3存在特异性核酸排列顺序。CXC趋化因子配体13、白细胞介... 抗N-甲基-D-天冬氨酸受体(NMDAR)脑炎是自身免疫性脑炎中最常见的类型之一,其发病机制与B细胞介导的体液免疫反应产生的抗NMDAR抗体有关。抗NMDAR脑炎患者B细胞表面受体互补决定区3存在特异性核酸排列顺序。CXC趋化因子配体13、白细胞介素-6、白细胞介素-17在B细胞迁移和浸润过程中起重要作用。目前,临床已开始使用利妥昔单抗和托珠单抗治疗抗NMDAR脑炎。未来,深入研究抗NMDAR脑炎中B细胞成熟和克隆分化的分子机制,有助于寻找抗NMDAR脑炎的生物标志物,为疾病的早期诊断和靶向治疗提供理论支持。 展开更多
关键词 抗N-甲基-D-天冬氨酸受体脑炎 b细胞 b细胞库 细胞因子 单克隆抗体
下载PDF
Factors Associated with Antibody Levels among Children Aged 15 to 59 Months Vaccinated against Hepatitis B during the Expanded Program on Immunization in Cameroon
9
作者 Antonin Wilson Ndjitoyap Ndam Alpha Hamed Béchir Ndam Mefire +4 位作者 Winnie Bekolo Guy Roger Nsenga Djapa Suzanne Ngo Um Sap Paul Koki Ndombo Elie Claude Ndjitoyap Ndam 《Open Journal of Gastroenterology》 CAS 2023年第2期91-98,共8页
Background: the hepatitis B virus infection remains a major public health problem worldwide. It can lead to a liver cirrhosis and/or hepatocellular carcinoma. The World Health Organisation (WHO) has recommended the im... Background: the hepatitis B virus infection remains a major public health problem worldwide. It can lead to a liver cirrhosis and/or hepatocellular carcinoma. The World Health Organisation (WHO) has recommended the implementation of generalised vaccination programs against hepatitis B. In Cameroon, this vaccine was introduced in the expanded program on immunization (EPI) in 2005, but few studies have assessed the immune response. Objective: the general objective of this study was to identify factors associated with antibody levels among children aged from 15 to 59 months vaccinated against hepatitis B during the EPI in Cameroon. Method: this was a cross-sectional study carried out from December 2021 to June 2022 in a paediatric centre of Yaoundé (Cameroon). We analysed the antibody level in children vaccinated against hepatitis B within the framework of the EPI. We enrolled children who had received a series of 3 intramuscular doses of hepatitis B vaccine at 6, 10 and 14 weeks after birth. Some children could receive a 4<sup>th</sup> booster dose between 12 months. The antibody level was assessed by measuring the anti-HBs in such children, aged 15 - 59 months. A good immunization was defined as a serum level of anti-HBs antibody level above 100 IU/mL;a poor immunization, for an anti-HBs antibody level between 10 and 100 IU/mL;and a non-immunization, for an anti-HBs antibody level < 10 IU/mL. Association between explored factors and poor or non-immunization was evaluated through the Chi square test. The significance threshold was defined at p < 0.05. Results: sixty subjects were included in the study with a slight female majority: 31 cases (52%). The average age was 38.5 ± 15.7 months (range 15 - 59 months). We found 32 (53%) cases of good immunization;21 (35%) of poor immunization;and 7 children (12%) with a non-immunization. The only factor associated with poor or non-immunization was the age between 37 - 59 months (p = 0.016). Conclusion: Anti HBs Antibody levels in children vaccinated against hepatitis B virus were globally satisfactory in our series. Results show an association between low antibody levels with older age (over 36 months), suggesting a circulating antibodies levels decrease over time, yet deemed protecting until 59 months. 展开更多
关键词 Hepatitis b VACCINATION CHILDREN antibody Levels IMMUNIZATION Cameroon
下载PDF
A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling
10
作者 Zheyue Wang Qi Tang +14 位作者 Bende Liu Wenqing Zhang Yufeng Chen Ningfei Ji Yan Peng Xiaohui Yang Daixun Cui Weiyu Kong Xiaojun Tang Tingting Yang Mingshun Zhang Xinxia Chang Jin Zhu Mao Huang Zhenqing Feng 《The Journal of Biomedical Research》 CAS CSCD 2023年第3期166-178,共13页
Although vaccines have been developed,mutations of SARS-CoV-2,especially the dominant B.1.617.2(delta)and B.1.529(omicron)strains with more than 30 mutations on their spike protein,have caused a significant decline in... Although vaccines have been developed,mutations of SARS-CoV-2,especially the dominant B.1.617.2(delta)and B.1.529(omicron)strains with more than 30 mutations on their spike protein,have caused a significant decline in prophylaxis,calling for the need for drug improvement.Antibodies are drugs preferentially used in infectious diseases and are easy to get from immunized organisms.The current study combined molecular modeling and single memory B cell sequencing to assess candidate sequences before experiments,providing a strategy for the fabrication of SARS-CoV-2 neutralizing antibodies.A total of 128 sequences were obtained after sequencing 196 memory B cells,and 42 sequences were left after merging extremely similar ones and discarding incomplete ones,followed by homology modeling of the antibody variable region.Thirteen candidate sequences were expressed,of which three were tested positive for receptor binding domain recognition but only one was confirmed as having broad neutralization against several SARS-CoV-2 variants.The current study successfully obtained a SARS-CoV-2 antibody with broad neutralizing abilities and provided a strategy for antibody development in emerging infectious diseases using single memory B cell BCR sequencing and computer assistance in antibody fabrication. 展开更多
关键词 SARS-CoV-2 neutralizing antibody single b cell bCR sequencing molecular modeling
下载PDF
Epidemic Japanese B encephalitis combined with contactinassociated protein-like 2 antibody-positive autoimmune encephalitis:A case report
11
作者 Pan Huang 《World Journal of Clinical Cases》 SCIE 2023年第6期1379-1384,共6页
BACKGROUND It is not uncommon to develop viral encephalitis.Epidemic Japanese B encephalitis infection combined with contactin-associated protein-like 2(CASPR-2)antibody-positive autoimmune encephalitis has not been r... BACKGROUND It is not uncommon to develop viral encephalitis.Epidemic Japanese B encephalitis infection combined with contactin-associated protein-like 2(CASPR-2)antibody-positive autoimmune encephalitis has not been reported at present.In clinical work,we need to consider more options.CASE SUMMARY A 32-year-old male worker presented with headache,fever and call-unresponsive presentation.Complete cranial magnetic resonance image showed symmetrical abnormal signals in bilateral medial temporal lobe,bilateral thalamus and basal ganglia.Improved lumbar puncture showed that cerebrospinal fluid protein and cell count increased significantly.Viral encephalitis was considered,and the patient's consciousness still increased rapidly after antiviral treatment.Further detection of Cerebrospinal fluid Japanese B encephalitis virus Polymerase Chain Reaction positive,serum autoimmune encephalitis antibody showed CASPR-2 antibody positive(1:320),the patient's condition gradually improved after plasma exchange treatment.3 mo later,the serum CASPR-2 antibody was negative and the patient's condition was stable.CONCLUSION This article reports the world’s first case of Epidemic Japanese B encephalitis infection combined with CASPR-2 antibody-positive autoimmune encephalitis,with a view to raising awareness. 展开更多
关键词 Epidemic Japanese b encephalitis Contactin-associated protein-like 2 antibody Autoimmune encephalitis
下载PDF
A1Bw亚型中多重抗体漏检的临床研究
12
作者 邹昕 范小杰 《检验医学与临床》 CAS 2024年第11期1651-1654,共4页
目的分析1例A1Bw亚型样本的血清学和分子生物学特征及交叉配血不合原因。方法采用试管法对该样本进行ABO血型血清学检测、吸收放散试验、唾液血型物质检测、酸化血清试验、ABO基因第1~7外显子扩增产物基因测序。以“ABO亚型”和“不规则... 目的分析1例A1Bw亚型样本的血清学和分子生物学特征及交叉配血不合原因。方法采用试管法对该样本进行ABO血型血清学检测、吸收放散试验、唾液血型物质检测、酸化血清试验、ABO基因第1~7外显子扩增产物基因测序。以“ABO亚型”和“不规则抗-B/抗-A抗体”为关键词,对中国知网数据库2020年1月至2023年8月发表的文献进行文献检索。结果该样本血清学表型为cisAB/A或ABx,同时血清中产生同种抗-Lea、抗-E抗体伴不规则抗-B抗体。ABO基因序列分析结果显示,ABO*A1.02/B.01杂合,且第7外显子发生c.721C/T基因突变,最终该血型判定为ABO*A1.02/BW.03基因型。文献检索结果显示,共检索到文献42篇,排除分子技术、肿瘤疾病等文献,最终纳入18篇文献。该文主要从亚型中不规则抗体检测的角度出发,重点叙述多重抗体漏检分析,总结当存在ABO血型以外的不规则抗体时,亚型中的不规则抗-B/抗-A抗体的检测流程。结论血清学试验结合分子生物学方法可更准确鉴定ABO亚型,正确鉴定亚型中不规则抗体是保障输血安全的前提。 展开更多
关键词 AbO亚型 不规则抗-b/抗-A抗体 抗-Lea抗体 抗-E抗体 AbO*A1.02/bW.03
下载PDF
B细胞在非感染性葡萄膜炎中的研究进展
13
作者 杨园缘 王芷若 +1 位作者 陈功 陈慧慧 《国际眼科杂志》 CAS 2024年第5期718-722,共5页
非感染性葡萄膜炎是一种严重威胁视力,治疗棘手的自身免疫性眼病。目前主流观点认为非感染性葡萄膜炎的发病机制是主要由CD4+T细胞介导的免疫失衡。但近年来许多证据表明B细胞也发挥关键作用,通过产生抗体、抗原提呈、分泌细胞因子、形... 非感染性葡萄膜炎是一种严重威胁视力,治疗棘手的自身免疫性眼病。目前主流观点认为非感染性葡萄膜炎的发病机制是主要由CD4+T细胞介导的免疫失衡。但近年来许多证据表明B细胞也发挥关键作用,通过产生抗体、抗原提呈、分泌细胞因子、形成异位淋巴结构等多种方式参与到实验性自身免疫性葡萄膜炎模型及人类葡萄膜炎中。针对B细胞的治疗已广泛应用于多种自身免疫性疾病。利妥昔单抗,一种B细胞抑制剂,在对传统皮质类固醇和免疫抑制剂治疗无效的难治性非感染性葡萄膜炎中发挥不错疗效。本文总结了B细胞在非感染性葡萄膜炎中的作用及细胞疗法,旨在为更深入的机制研究提供理论基础,并为开发精准有效的防治策略开辟新视角。 展开更多
关键词 b细胞 非感染性葡萄膜炎 免疫失衡 抗体 抗原提呈 细胞因子 利妥昔单抗
下载PDF
新型冠状病毒感染与CAR-T耐药双重挑战下的格菲妥单抗治疗:难治性弥漫大B细胞淋巴瘤1例报告
14
作者 毕江涵 张炎 王为 《中国癌症防治杂志》 CAS 2024年第5期566-570,共5页
本文总结1例嵌合抗原受体T(chimeric antigen receptor T,CAR-T)细胞治疗失败的难治性弥漫大B细胞淋巴瘤患者,在合并新型冠状病毒(coronavirus disease 2019,COVID-19)情况下接受格菲妥单抗治疗后获得完全缓解,且未见COVID-19感染加重... 本文总结1例嵌合抗原受体T(chimeric antigen receptor T,CAR-T)细胞治疗失败的难治性弥漫大B细胞淋巴瘤患者,在合并新型冠状病毒(coronavirus disease 2019,COVID-19)情况下接受格菲妥单抗治疗后获得完全缓解,且未见COVID-19感染加重等其他严重不良反应的治疗经验,同时回顾文献中格菲妥单抗治疗难治性弥漫大B细胞淋巴瘤的疗效,以及双特异性抗体在合并COVID-19的淋巴瘤患者中的安全性。 展开更多
关键词 弥漫性大b细胞淋巴瘤 嵌合抗原受体T细胞 格菲妥单抗 双特异性抗体 新型冠状病毒 淋巴瘤
下载PDF
Is there a need for universal double reflex testing of HBsAg-positive individuals for hepatitis D infection?
15
作者 Zaigham Abbas Minaam Abbas 《World Journal of Hepatology》 2024年第3期300-303,共4页
Hepatitis D virus(HDV)can infect HBsAg-positive individuals,causing rapid fibrosis progression,early decompensation,increased hepatocellular carcinoma risk,and higher mortality than hepatitis B virus(HBV)mono-infectio... Hepatitis D virus(HDV)can infect HBsAg-positive individuals,causing rapid fibrosis progression,early decompensation,increased hepatocellular carcinoma risk,and higher mortality than hepatitis B virus(HBV)mono-infection.Most countries lack high-quality HDV prevalence data,and the collection techniques employed often bias published data.In recent meta-analyses,HDV prevalence in HBsAg-positive patients reaches 5%-15%and is even significantly higher in endemic areas.Since HBV vaccination programs were implemented,HDV prevalence has decreased among younger populations.However,owing to immigrant influx,it has increased in some Western countries.The current practice of HDV screening in HBsAg-positive individuals is stepwise,based on physician’s discretion,and limited to at-risk populations and may require numerous visits.Double reflex testing,which includes anti-HDV testing in all HBsAg-positive individuals and then HDV RNA testing for anti-HDV-positive ones,is uncommon.Reflex testing can identify more HDV infection cases and link identified patients to further care and follow-up.Moreover,laboratory-based double reflex screening is less biased than physician-led testing.Therefore,health-care providers should learn about reflex testing,and federal and provincial hepatitis control programs should implement laboratory-based double reflex testing to obtain reliable HDV prevalence estimates.The test’s cost-effectiveness depends on the number of HBV-positive patients screened to identify one HDV-positive patient.Such testing may be viable in areas with low HBsAg but high HDV prevalence.However,its economic impact on areas with low HDV prevalence needs further study. 展开更多
关键词 Anti-hepatitis D virus antibody HbSAG Hepatitis D virus RNA Hepatitis b Hepatitis D Reflex testing
下载PDF
香港牡蛎cyclin B基因组织表达特征及其多克隆抗体制备
16
作者 邱衡通 许贵林 +3 位作者 李宛怡 周齐家 刘小宁 朱俊霖 《南方农业学报》 CAS CSCD 北大核心 2024年第4期909-919,共11页
【目的】明确香港牡蛎(Crassostrea hongkongensis)B型细胞周期蛋白基因(cyclin B)组织表达特征,并通过原核表达融合蛋白制备多克隆抗体,为探究香港牡蛎cyclin B基因在环境胁迫下的表达特征及揭示cyclin B调控贝类细胞周期的作用机制提... 【目的】明确香港牡蛎(Crassostrea hongkongensis)B型细胞周期蛋白基因(cyclin B)组织表达特征,并通过原核表达融合蛋白制备多克隆抗体,为探究香港牡蛎cyclin B基因在环境胁迫下的表达特征及揭示cyclin B调控贝类细胞周期的作用机制提供理论依据。【方法】克隆香港牡蛎cyclinB基因c DNA序列,通过SignalP-5.0、ProtParam、TMHMM2.0、NetSurfP2.0及Bioedit7.0等软件进行生物信息学分析,采用实时荧光定量PCR检测cyclinB基因在香港牡蛎不同组织中的表达情况;构建重组质粒pET32a-cyclin B并运用原核表达系统诱导表达融合蛋白,经Ni-NTA镍离子亲和层析柱纯化后免疫BALB/c小鼠制备鼠源多克隆抗体,然后以间接ELISA检测多克隆抗体效价、Western blotting检测多克隆抗体特异性。【结果】香港牡蛎cyclinB基因cDNA序列全长2353bp,包括1299bp的开放阅读框(ORF)、103 bp的5’非编码区(5’-UTR)和951 bp的3’非编码区(3’-UTR),共编码432个氨基酸残基。香港牡蛎cyclin B蛋白相对分子量为49.13 kD,理论等电点为7.16,不含信号肽和跨膜结构域。香港牡蛎cyclin B氨基酸序列包含2个保守的周期蛋白框,与来自同属的长牡蛎cyclin B氨基酸序列相似性最高(98.8%),基于cyclin B氨基酸序列相似性构建的系统发育进化树也显示香港牡蛎与长牡蛎的亲缘关系最近。cyclin B基因在香港牡蛎的闭壳肌、外套膜、性腺、鳃、唇瓣、消化腺等组织中均有表达,以性腺中的相对表达量最高,显著高于其他组织中的相对表达量(P<0.05)。通过原核表达获得的融合蛋白cyclin B具备良好免疫原性,且主要以包涵体形式存在;以其免疫BALB/c小鼠制备出的鼠源多克隆抗体效价大于1∶64000,能特异识别香港牡蛎性腺中的cyclin B蛋白。【结论】香港牡蛎cyclin B基因具有较高的保守性,其氨基酸序列包含2个保守的周期蛋白框;香港牡蛎cyclin B基因表达具有广谱性和组织差异性,在调控生殖细胞减数分裂过程中发挥作用。通过原核表达体系及免疫注射BALB/c小鼠制备获得的cyclin B鼠源多克隆抗体具有高效价,能特异识别香港牡蛎性腺中的cyclin B蛋白,为进一步探究香港牡蛎cyclin B的生物学功能与表达调控机理提供了技术支持。 展开更多
关键词 香港牡蛎 cyclin b基因 表达特征 多克隆抗体 减数分裂
下载PDF
吸收IgG抗-AB抗体后IgG抗-A/抗-B抗体效价预测ABO-胎儿新生儿溶血病的价值
17
作者 程晨 张怡 +2 位作者 陈怡静 骆群 卓海龙 《中国实验血液学杂志》 CAS CSCD 北大核心 2024年第6期1903-1908,共6页
目的:分析吸收IgG抗-AB抗体后O型孕妇血浆中IgG抗-A/抗-B抗体效价对ABO-胎儿新生儿溶血病(ABO-HDFN)发生的预判价值。方法:选取2020年2月-2020年9月北京市血液中心母亲血型为O型的新生儿高胆红素血症样本235例,采用微柱凝胶卡检测母亲血... 目的:分析吸收IgG抗-AB抗体后O型孕妇血浆中IgG抗-A/抗-B抗体效价对ABO-胎儿新生儿溶血病(ABO-HDFN)发生的预判价值。方法:选取2020年2月-2020年9月北京市血液中心母亲血型为O型的新生儿高胆红素血症样本235例,采用微柱凝胶卡检测母亲血浆IgG抗-AB抗体吸收前后IgG抗-A/抗-B抗体效价,并统计ABO-HDFN的发生情况。分析比较IgG抗-AB抗体吸收前后IgG抗-A/B抗体效价变化及不同效价下ABO-HDFN的发生率,并采用受试者工作特征(ROC)曲线分析吸收IgG抗-AB抗体后O型孕妇血浆中IgG抗-A/抗-B抗体效价水平对ABO-HDFN的诊断效能。结果:本研究选取的235例母亲血型为O型的新生儿高胆红素血症样本中,新生儿血型为A型的有127例,其中38例确诊为ABO-HDFN;血型为B型的有108例,其中31例确诊为ABO-HDFN。235例样本吸收IgG抗-AB抗体前后,IgG抗-A/抗-B抗体效价差异显著(P<0.05)。在69例ABO-HDFN确诊病例中,无论是否吸收IgG抗-AB抗体,ABO-HDFN的发生率都会随着IgG抗-A/抗-B抗体效价的升高而升高,但未吸收IgG抗-AB前,抗-A/抗-B抗体效价均≥1∶512,而吸收后抗-A/抗-B抗体效价则出现明显降低,整体下降了3个滴度,均≤1∶512。ROC曲线分析显示,吸收IgG抗-AB抗体前后IgG抗-A/抗-B抗体效价均可作为诊断ABO-HDFN的效能指标;但吸收IgG抗-AB抗体前后IgG抗-A/抗-B抗体效价诊断ABO-HDFN的效能存在一定差异(P<0.05),吸收后的AUC值均大于吸收前,表明吸收IgG抗-AB抗体后IgG抗-A/抗-B抗体效价诊断ABO-HD-FN的效能优于吸收前(P<0.05)。结论:O型产妇血浆吸收IgG抗-AB抗体后测得的IgG抗-A/抗-B抗体效价越高,ABO-HDFN发生率越高;且吸收IgG抗-AB抗体后IgG抗-A/抗-B抗体效价诊断ABO-HDFN效能高于吸收前的诊断效能。 展开更多
关键词 AbO-胎儿新生儿溶血病 新生儿高胆红素血症 IgG抗-Ab抗体 IgG抗-A/抗-b抗体效价
下载PDF
多次输血产生抗-C、抗-JK^(b)联合抗-Wr^(a)致疑难配血1例
18
作者 崔丛丛 郝萧 《中国输血杂志》 CAS 2024年第10期1197-1200,共4页
目的研究1例多次输血患者疑难配血的原因,探讨如何降低多次输血患者产生同种抗体的风险。方法结合临床资料分析,患者血清抗体筛查及鉴定、聚乙二醇抗球蛋白实验及二巯基乙醇法等血清学检测抗体特异性。结果患者血清不规则抗体经鉴定为... 目的研究1例多次输血患者疑难配血的原因,探讨如何降低多次输血患者产生同种抗体的风险。方法结合临床资料分析,患者血清抗体筛查及鉴定、聚乙二醇抗球蛋白实验及二巯基乙醇法等血清学检测抗体特异性。结果患者血清不规则抗体经鉴定为抗-C、抗-Wr^(a),采用聚乙二醇抗球蛋白加强实验后鉴定出患者血清中还存在抗-Jk^(b)。二巯基乙醇法区分出抗-Wr^(a)为IgM型,效价为16,抗-C效价为8,抗-Jk^(b)效价<1。结论发现1例复合抗-C、抗-Jk^(b)、抗-Wr^(a)引起的疑难配血,通过加强实验提高了Kidd系统抗体的检测效率,及时为患者提供了相匹配的血液。 展开更多
关键词 抗-C 抗-Jk^(b) 抗-Wr^(a) 抗体漏检
下载PDF
免疫治疗在复发/难治性急性B淋巴细胞白血病中的应用
19
作者 初琪慧 高彤 +1 位作者 曲素欣 闫美兴 《中国药房》 CAS 北大核心 2024年第7期886-889,共4页
免疫治疗作为一种新兴的治疗方法,被证实能够改善复发/难治性急性B淋巴细胞白血病(B-ALL)患者的预后,具有良好的应用前景。其中,嵌合抗原受体修饰的T细胞免疫疗法(CAR-T)和单克隆抗体免疫疗法显示出巨大的应用潜力,多款药物已被批准上... 免疫治疗作为一种新兴的治疗方法,被证实能够改善复发/难治性急性B淋巴细胞白血病(B-ALL)患者的预后,具有良好的应用前景。其中,嵌合抗原受体修饰的T细胞免疫疗法(CAR-T)和单克隆抗体免疫疗法显示出巨大的应用潜力,多款药物已被批准上市。本文对上述两种疗法治疗复发/难治性B-ALL的临床应用情况进行归纳总结,得出CAR-T是一种个体化免疫疗法,理想靶标的选择是其发挥作用的重要环节,目前其临床研究中理想的靶点包括CD19、CD22、CD19/CD22;单克隆抗体主要包括博纳吐单抗和奥加伊妥珠单抗,其对复发/难治性B-ALL显示出良好的疗效。免疫治疗比常规化疗显示出更优异的治疗效果,拓宽了复发/难治性B-ALL治疗方案的选择面。 展开更多
关键词 复发/难治性急性b淋巴细胞白血病 免疫治疗 CAR-T疗法 单克隆抗体
下载PDF
O型血孕妇产前血清IgG抗A(B)抗体效价积分评估HDN发生价值
20
作者 何烁晴 洪立闩 +1 位作者 吴永美 孙月娥 《中国计划生育学杂志》 2024年第7期1687-1691,共5页
目的:探究产前O型血孕妇血清中免疫球蛋白G(IgG)抗A(B)抗体效价积分对新生儿溶血(HDN)发生的预测价值。方法:回顾性选取2022年1月-2023年12月本院收治的101例O型血孕妇临床资料,根据新生儿是否发生HDN分为为HDN组(n=26)和非HDN组(n=75)... 目的:探究产前O型血孕妇血清中免疫球蛋白G(IgG)抗A(B)抗体效价积分对新生儿溶血(HDN)发生的预测价值。方法:回顾性选取2022年1月-2023年12月本院收治的101例O型血孕妇临床资料,根据新生儿是否发生HDN分为为HDN组(n=26)和非HDN组(n=75)。比较两组临床资料、产前血清中IgG抗A(B)抗体效价积分等。采用Spreaman相关分析分析孕妇血清中IgG抗A(B)抗体效价积分与HDN发生的相关性,受试者工作曲线(ROC)分析O型血孕妇血清中IgG抗A(B)抗体效价积分对HDN发生的预测价值。结果:HDN组孕妇产前血清IgG抗A(B)抗体效价均高于非HDN组,当产前血清的IgG抗A(B)抗体效价相同时,HDN组孕妇的血清IgG抗A(B)抗体效价积分明显于非HDN组(均P<0.05);Spearman相关分析,孕妇产前血清IgG抗A(B)抗体效价积分与HDN发生呈正相关(r=0.666,P<0.001);ROC曲线分析,O型血孕妇血清中IgG抗A(B)抗体效价积分预测HDN发生曲线下面积0.874,截断值54.88,灵敏度84.0%、特异度94.7%。结论:产前O型血孕妇血清中IgG抗A(B)抗体效价积分新生儿发生HDN概率呈正相关,且对HDN的发生有一定预测价值。 展开更多
关键词 O型血孕妇 血清IgG抗A(b)抗体效价 效价积分 新生儿溶血症 临床评估
下载PDF
上一页 1 2 81 下一页 到第
使用帮助 返回顶部